| Technology Name | Briefcase | Lead Researcher |
|---|---|---|
Categories
Oncology, Cancer, Diagnostics
Development Stage
In vitro proof of concept and small animals
Patent Status
PCT application filed
Market
Cancer testing is currently one of the most important growth opportunities diagnostics ... More | Karni Rotem | |
Background
Currently there are no molecules that can directly inhibit the activity of splicing factors. We created decoy oligonucleotides that directly bind and inhibit the splicing activity of splicing factors without affecting their ... More | Karni Rotem | |
Background
Epigenome editing by DNA methylation or demethylation of regulatory sequences are widely required in medicine and in biomedical research, but current technologies are non-specific and provide unpredictable effects. This technology ... More | Hellman Asaf | |
Background
Mutations in specific genes or proteins variability can dramatically enhance our probability to get cancer. Similarly, genetic variability could have the opposite effect and actually protect us from cancer, other diseases and even ... More | Tabach Yuval | |
Keywords
cell free DNA diagnosis, liquid biopsies, methylation patterns, histone modification
Current development stage
TRL3 - hypothesis testing and intial POC demonstrated in limited # of in-vitro modelsApplication
The existing sequence ... More | Friedman Nir | |
Background
PCR using bisulfite-treated DNA as a template, which is followed by next generation sequencing (NGS), has a major potential as a diagnostic tool, by identifying DNA derived from specific tissue based on cell type-specific methylation ... More | Dor Yuval | |
A novel and personalized method for identifying the optimal anti-cancer treatment, through simultaneous detection of unique tumor sensitivities to multiple drugs or drug combinations in a multiplex manner, (this can be done) in vitro on cancer ... More | Willner Itamar | |
Background
The therapeutic activity of most anticancer drugs in clinical use is limited by their general toxicity to proliferating cells, including some normal cells. Although chemists continue to develop novel cytotoxic agents with unique ... More | Willner Itamar | |
Background
DNA mutations in mitochondrial proteins/enzymes (nuclear encoded) that may lead to disease are present in approximately 1 in 8,000 individuals.
Any treatment for mitochondrial diseases must be capable of targeting and crossing the ... More | Galski- Lorberboum Haya | |
Background
With continuous increase in the elderly population, many age-related health problems have become a major healthcare issue.
Attenuating deleterious age-related processes taking place in multiple organs is highly desirable.
Our ... More | Keshet Eli | |
Once-daily, sustained-release Sirolimus delivery system
Categories
Oral Cavity, Oncology/Cancer, Sustained Release, Drug Delivery
Development Stage
Prototypes tested in vitro; pharmokinetic and pharmacodynamic testing in human volunteers ... More | Friedman Michael | |
Our Innovation
The finding by HUJI researchers uncovers a novel structure of an outer mitochondrial membrane [Fe-S] protein (mitoNEET) determined by X-ray crystallography (Fig 1)
MitoNEET is an outer mitochondrial membrane protein that ... More | Nechushtai Rachel | |
Background
Fatty liver disease - Non alcoholic fatty liver disease (NAFLD) is a continuum of diseases that include simple steatosis and non-alcoholic steatohepatitis (NASH) ultimately leading to cirrhosis, hepatocellular carcinoma (HCC) and/or ... More | Tirosh Oren | |
Categories
Superactive High Afinity Leptin antagonist, mutein, multiple sclerosis, inflammatory bowel syndrome, rheumatoid arthritis, fibrosis, cardiovascular disease, CKD Cachexia, Osteoarthritis
Development Stage
(1) In vivo tests in ... More | Gertler Arieh | |
Yousef Najajreh, Al Quds University
Background
A growing number of peoples worldwide are suffering from the health consequences of obesity.
As for today, Only one drug is currently approved for long-treatment of obesity-the lipase ... More | Avraham Yosefa | |
Prof. Yaron Ilan, Department of Human Nutrition and Metabolism and Liver Unit Hadassah Hospital
Background
To date, there is no effective treatment of liver diseases with the related Hepatic-Encephalopathy symptoms. It is established that ... More | Avraham Yosefa | |
Our Innovation
Based on a provocative working hypothesis, we most probably identified the molecular origin of insulin resistance (IR). Systemic IR is induced via post-translational modification (PTM) of liver key regulatory proteins. We ... More | Ben-Sasson Shmuel | |
Categories
Small molecules, anti-inflammatory treatment
Development Stage
In-vivo proof of concept
Patent Status
Patent application filed
Market
Inflammation indications: acute pancreatitis, acute live damage, fatty liver damage, ... More | Weinstock-Rosin Marta | |
Background
Primary human hepatocytes are isolated from organs rejected from transplantation. Cells are expensive, show massive batch-to-batch variability and fail to proliferate in culture. Hepatocytes are routinely used by the pharmaceutical ... More | Nahmias Yaakov | |
Category
Life Sciences ,pharma
Keywords
Non-alcoholic fatty liver disease, NAFLD, Liver Toxicity, metabolic diseases,
Current development stage
General list: TRL3 Experimental proof of concept
Partnership ... More | Tirosh Oren |